Home > Boards > US OTC > Delisted > Insys Therapeutics Inc. (fka INSYQ)

$36! TODAY "Insys in

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
mlkrborn Member Profile
 
Followed By 39
Posts 7,816
Boards Moderated 1
Alias Born 01/04/06
160x600 placeholder
Apple Security Chief Offered iPads to Police as a Bribe for Gun Permits, Prosecutors Allege
Apple Inc.'s head of security has been indicted on bribery charges for a scheme in which prosecutors allege he offered iPads to secure gun permits for his company's employees.
Syncrude JV Owners Agree in Principle for Suncor to Become Operator
Top Company News of the Day
Blackrock to Buy Equity-Index Provider Aperio for $1 Billion
Top Stories of the Day
ADRs Gain Overall Monday; AstraZeneca's ADRs Weaken After Vaccine News
Correction to GM Recall Article
Canada to Present Fall Economic Update on Nov. 30 -- Update
Dow Rises on Covid-19 Vaccine Results
Dow Rises on Covid-19 Vaccine Results -- Update
USDA Crop Progress: Winter Wheat Condition/Progress-Nov 23
New York City Needs Federal Funds to Recover Economic Footing, Mayor Says
Canada to Present Fall Economic Update on Nov. 30
Corn Higher as Increased Export Demand Confirmed
Virtual Stores Present New Experiences to Shoppers Who Miss the In-Store Feeling
Micron Technology on Track for Highest Close Since September 2000 -- Data Talk
Canadian Government, Central Bank Helped Avoid Broad Financial System Stress -- Bank of Canada Official
GDP Seen Steady, New Home Sales Expected to Rise -- Data Week Ahead -- Update
Morgan Stanley on Track for Highest Close in Over 13 Years -- Data Talk
Dupont's Up-and-Down History Shaped Biden's Views on Business
Disney Cruise Line Cancels All Sailings Through Jan. 31
AstraZeneca, Oxford Covid-19 Vaccine Up to 90% Effective in Late-Stage Trials -- 6th Update
mlkrborn   Friday, 12/13/13 11:10:41 AM
Re: None
Post # of 1721 
$36! TODAY "Insys in hot water over marketing practices
Insys Therapeutics (NASDAQ: INSY ) is down nearly 20% pre-market this morning after word hit the Street late yesterday about the company being investigated for its marketing practices for Subsys.

Subsys was approved by the Food and Drug Administration in 2012 as a sublingual spray used for pain relief in opioid-tolerate cancer patients. Since coming on the market last year, sales have now risen nearly 1,000% , pushing Insys shares up an eye-popping 500% year to date. According to the company's statement on the matter, it's cooperating with the investigation.

Is this drop panic-worthy? My take is that the market is getting ready to overreact again to another investigation into marketing practices that may or may not result in anything. Similar allegations have been hanging over Questcor Pharmaceuticals for over a year now, and there are lessons from that case that can be applied to Insys today.

Firstly, these investigations typically take years to resolve. And in my experience, they generally result in a fine that isn't a major issue for drugs churning out hundreds of millions in sales. Although I'd like to see more details of the investigation before making a final call, Foolish investors should dig deeper into this legal matter to see if today's drop is creating a good buying opportunity. Buying fear is often a great long-term investing strategy."MOTLEY FOOL

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences